Mutated H3N2 flu circulates early in the Northern Hemisphere: experts recommend immunization

Health authorities in Reino Unido and other Hemisfério Norte countries report an early start to the flu season in 2025, driven by the subclade K variant of the influenza A(H3N2) virus. Essa mutation, identified after the formulation of the annual vaccine, dominates samples in nations like Inglaterra and Canadá, with hospitalizations up 56% compared to the previous year. Especialistas warn of a potentially severe season, but emphasize that immunization remains essential to reduce complications.

The early outbreak especially affects young adults and children, with 90% of recent samples testing positive for H3N2 in Reino Unido. Agência of Segurança Sanitária of Reino Unido (UKHSA) issued alerts for Sistema Nacional of Essa strain evolved with seven genetic mutations during the summer, increasing its immune evasion capacity, according to global data deposited in GISAID.

The global circulation of subclade K represents 33% of H3N2 sequences analyzed between May and November 2025, with almost half in União Europeia. Países like Japão and Canadá face early epidemics, and projections indicate dominance of this variant in Hemisfério Norte. Apesar of the discrepancy with the vaccine, initial studies show protection against severe forms of the disease.

Early onset of H3N2 flu worldwide

The 2025 influenza season started weeks earlier than expected in regions such as Europa and América of Norte, with cases peaking in October. No Reino Unido, hospital admissions for flu reached 1,717 per day in the last week of November, seven times more than in 2023. Essa acceleration is due to subclade K, which spread rapidly after mutations in hemagglutinin, a key protein for infection.

UKHSA data reveals that 87% of H3N2 samples in Inglaterra belong to this subclade since August. No Canadá, similar proportions were observed in children aged 5 to 19 years, the group with the highest detection. Especialistas attribute the early advance to low population immunity against this form, which is absent in recent circulation.

Priority groups for free vaccination

The NHS offers free flu vaccinations to vulnerable populations, prioritizing collective protection.

• People aged 65 and over, due to the high risk of hospitalization.
• Individuals with chronic conditions such as diabetes or heart problems.
• Pregnant women, to safeguard mother and fetus.
• Nursing home residents and caregivers for the elderly or disabled.

Health workers in direct contact also access the dose via their employer. Essa strategy aims to contain outbreaks in collective environments, where transmission is facilitated.

Children aged 2 to 11 receive nasal spray, which is effective for this age group. Vaccination coverage increased among pregnant women and children aged 2 to 3 years compared to 2024, but fell slightly among the elderly.

Vaccine efficacy against subclade K

The 2025-2026 vaccine, formulated with the J.2 strain of H3N2, is out of step with the K subclade, which emerged after the selection of lineages by the WHO in February. Testes antigens show low reactivity with post-infection ferret sera, indicating reduced neutralization. However, preliminary data from the UKHSA suggests an effectiveness of 70% to 75% in children receiving emergency care.

In adults, protection varies from 30% to 40%, focusing on preventing serious hospitalizations. Estudos in Canadá confirm that 51 of 59 H3N2 samples tested exhibit a lower response to the current vaccine. Apesar In addition, immunization reduces the duration and intensity of symptoms, according to reports from the CDC in the USA.

The WHO monitors developments, but reinforces that mutations do not alter the action of antivirals such as oseltamivir. Para the next season, adjustments to the vaccine composition are likely, based on global sequences.

Recommendations for purchasing a private vaccine

Healthy individuals not entitled to a free dose can purchase the vaccine in pharmacies for around R$100 to R$150, depending on the country. No Brasil, SUS prioritizes risk groups, but private options guarantee broad access. Especialistas recommend immediate application, as the peak of cases approaches with the end of year festivities.

The dose protects throughout the season, with immunity peaking in two weeks. Contraindicações include severe allergies to components, such as eggs, but most tolerate them well. Farmacêuticos provide guidance on interactions with other vaccines, such as the one against Covid-19.

Symptoms that differentiate flu from cold and Covid

Identifying H3N2 flu helps with early management, avoiding complications such as pneumonia. The signs appear abruptly, contrasting with the gradual nature of colds.

The infection causes high fever, muscle pain and intense exhaustion, requiring absolute rest. Tosse dryness and extreme fatigue mark the presentation, unlike the nasal congestion prevalent in colds.

In Covid-19, similar symptoms are added to loss of smell or diarrhea, guiding diagnostic tests. Monitoramento at home includes hydration and isolation, with seeking a doctor if breathing worsens.

Complementary prevention measures

Basic hygiene reinforces the barrier against airborne transmission of subclade K, which infects 100 to 140 people per mutated case. Lavar hands with soap for 20 seconds removes viral particles, reducing risk by 20%.

Indoor ventilation dilutes aerosols, especially at family gatherings. Limpeza touching surfaces, such as door handles, with approved disinfectants cuts chains of contagion.

Wearing masks in crowded places protects vulnerable people, in line with WHO guidelines. Evitar contact with sick people and postponing trips during peaks minimizes collective exposure.

Global impact of the H3N2 mutation

Subclade K has spread to all continents since May 2025, with detections in Ásia, África and Américas. No Japão, an epidemic was declared in November, with a severe outbreak in schools. Essa genetic divergence, with eight substitutions in the hemagglutinin, does not increase lethality, but increases contagion in populations with low immunity.

In União Europeia, almost 50% of H3N2 sequences are from this variant, putting pressure on healthcare systems. Relatórios from ECDC classify the risk as moderate, but predict co-circulation with H1N1. Continuous Vigilância through the global GISAID network ensures updates for future vaccines.

In the US, viral concentrations in sewage rise, signaling an imminent post-holiday spike. Autoridades like CDC insist on universal vaccination from six months onwards, even with mismatch, to mitigate hospital overload.

The 2025 season highlights the need for annual adaptation to viral developments, with a focus on equity of access. Dados of real effectiveness will guide refinements, keeping the flu as a controllable disease.